These mass and activity amounts were selected based on those previously reported for SPECT imaging of HER2-positive BC in humans using 111In[In]DTPA-trastuzumab (100–150 MBq; 5 mg) (Perik et al. 2006). Here, ERBB2 is linked to breast cancer.